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Abstract 
Our biocompatible packaging concept for implantable 
electronic systems combines biocompatibility, hermeticity 
and extreme miniaturization. In a first phase, all chips are 
encapsulated in order to realize a bi-directional diffusion 
barrier preventing body fluids to leach into the package 
causing corrosion, and preventing IC materials such as Cu to 
diffuse into the body, causing various adverse effects. Various 
clean room materials are tested with respect to their 
suitability as encapsulation material. In a second phase of the 
packaging process, all chips of the final device should be 
electrically connected, applying a biocompatible metallization 
scheme using eg. gold or platinum. Device assembly is the 
final packaging step, during which all system components will 
be interconnected. To provide sufficient mechanical support, 
all these components are embedded using a biocompatible 
elastomer such as PDMS. 
 
INTRODUCTION 
Traditionally an implantable electronic device such as a 
pacemaker is packaged in a rigid titanium (Ti) box to ensure 
hermetic and biocompatible packaging of the microelectronic 
device. Unfortunately, this Ti box is often much larger 
compared to the electronics inside, hence a larger insertion 
wound is needed during implantation. Moreover, the Ti-box is 
a rigid package, which is in strong contrast with the soft 
tissue. Both the size and the rigidity of the Ti package might 
result in a pronounced Foreign Body Reaction (FBR), a clear 
infection risk upon implantation, and adverse effects such as 
irritation of surrounding tissue during device use.  
To decrease the problems listed above, the miniaturization 
technologies in packaging of microelectronics should be 
extended towards packaging of implanted medical devices, 
resulting in smaller implants. Additionally, by selecting proper 
materials, the final package can be made soft and biomimetic, 
resulting in a comfortable implantable device, causing limited 
FBR and adverse effects.   
NOVEL IMPLANTABLE PACKAGING CONCEPT 
Our implantable package concept is illustrated in Fig. 1. In the 
first phase, individual dies are encapsulated by top and 
bottom capping layers which should provide an excellent 
hermetical enclosure for each die. To avoid any influence of 
possible pinholes, the encapsulation consists of more than 
one layer. Obviously the capping layers should be 
biocompatible, which means that the material should not 
cause harm to the body.  Biocompatibility is a contextual 
concept, depending on duration and type of body contact, 



































Fig. 1. Proposed miniaturized implantable packaging.  
 (1) all chips are individually encapsulated by insulating and 
conductive diffusion barriers using a wafer level process;   
(2) biocompatible chip interconnect and embedding of 
multiple chips using a flexible polymer such as polyimide;   
(3) final system assembly including biocompatible 
metallization and embedding in a soft biomimetic polymer. 
imposed on the material to avoid any harm to the patient. 
Furthermore, the die encapsulation layers and electrodes (see 
Fig. 1, Phase 1) should also form a bi-directional diffusion 
barrier: no body fluid should leach into the device and 
harmful IC materials such as Copper (Cu) should not diffuse 
into the body tissue. 
In a second phase of the packaging process, all chips of the 
final device should be electrically connected. Gold (Au) or 
platinum (Pt) metallization is interesting for implants, due to 
the excellent biocompatibility and corrosion resistance.  A 
disadvantage is their high cost; hence attention needs to be 
paid at a cost-effective deposition/patterning technique. The 
performance of electrodes being in direct contact with the 
tissue (biopotential sensors) is improved when locally the Au 
or Pt is covered by iridium oxide (IrOx).  
During phase 3 -the final device assembly- all system 
components such as electronics, passives, a battery, etc. will 
be interconnected. To provide sufficient mechanical support, 
all components are embedded using a biocompatible 
elastomer which should be biomimetic (flex, soft material cfr. 
tissue) in order to reduce the patient’s body reaction upon 
implantation. 
PHASE 1:  DIE ENCAPSULATION 
Standard IC processing is used for chip fabrication, followed 
by a dedicated wafer level post process for this biocompatible 
and hermetic chip encapsulation. A brief description is given 
below, for more info see [1]. Thinned dies with sloped edges 
are encapsulated by a stack of standard clean room materials, 
as indicated in Fig. 2. Both insulating and conductive materials 
are needed. Related to the processing sequence, all top layers 
should be deposited at 400°C max, while for the bottom 
layers 200°C is the limit. It is a challenge to obtain good step 
coverage using these lower temperatures, but after some 









Fig. 2 : Cross-section of an encapsulated chip showing the 








Fig. 3. A dedicated deposition process for SiO2 results in a die 
encapsulation with excellent step coverage. 
DIE ENCAPSULATION MATERIALS: GENERAL CONSIDERATIONS 
Two series of materials are investigated:  
(a) insulating materials: SiO2 (Ox) and SixNy (N), deposited at 
a medium (M) or low (L) temperature of 400°C  or 200°C 
(further called OxM, NM, and OxL, NL). 
(b) conductive materials: well-known clean room materials 
with interesting barrier properties are: titanium (Ti), Ti-nitride 
(TiN), tantalum (Ta) and Ta-nitride (TaN) [2-4].  
 
The capping materials need to have various properties:  
(1) suitable biocompatibility  
(2) excellent bi-directional diffusion barrier 
(3) good stability in biofluids 
 
 
(1) Suitable biocompatibility  
Biocompatibility tests will investigate if a material causes 
harm to the body, a first and very important test is the so-
called ‘cytotoxicity test’. We investigate cytotoxicity according 
to the ISO 10993-5 standard regarding biocompatibility, using 
both co-culture and immersion tests using primary cells such 
as cardiomyocytes (Fig.4). After 5 days cell culture, the cell 
viability is calculated (viability: amount of healthy cells 
divided by total amount of cells). The cell condition is made 
visible by ‘live/dead cell assays’: fluorescent dyes will color 
healthy cells green and dead cells red.  For more test details 
see [5].  
As an example, the cytotoxicity results for the oxide and 
nitride layers are shown in Fig. 5. Cell viability should not 
differ more than 10% from the control result. We proved that 





















Fig 4: Test protocol for cytotoxicity tests and  
diffusion barrier tests 
 (2) Tests on bidirectional diffusion barrier properties 
Two types of tests are needed for diffusion characterisation 
of barrier layers: (a) test of diffusion of Cu through the barrier 
layer, done by Cu sensitive cell cultures and (b) evaluation of 
fluid leaching through the barrier layer, done by Cu corrosion 
tests during/after submersion. 
For these tests, we typically use 100nm thick layers of the 
material under test. For later encapsulation, the thickness of 












Fig 5. Cadiomyocytes viability after co-culture tests  
on insulating barrier materials. C- is the negative control or cell 
culture reference, having a viability of 80% in this test. 
Diffusion of harmful IC materials into the tissue is tested by 
immersing Cu layers encapsulated by 100nm of the material 
under test, followed by a 5-day primary cell culture (See Fig. 4 
for test protocol, more details in [5]). For the insulating 
materials, results are plotted in Fig.5. The films deposited at 
400°C (OxM and NM) have better barrier properties to stop 
copper diffusion. For the conductors, Ti and TaN performed 
well, while TiN and Ta are weaker in stopping diffusion.  
To ensure that a good diffusion barrier is obtained, we will 
always use stacks of conductive materials such as Ti/TiN and 
SiO2/SixNy. The optimum layer thickness is dependent on the 
implantation duration and site in the body.  
(3) Test of interaction of materials with biofluids 
Essential is also to investigate the bio-stability of the 
encapsulating materials when immersed for a long time in 
various types of bio-fluids (saline, cell culture medium,..). 
Since immersion times might be unpractical long, accelerated 
tests should be considered (see further). 
 (4)  Accelerated diffusion test and bio-stability test 
Diffusion evaluation based on cell co-culture tests is typically 
limited to a duration of 5-6 days, longer tests will result in cell 
death due to overpopulation or aging of the medium. This 
short test period is in contrast with the use of long term 
implants, i.e. a cochlear implants will remain 50 years or  
longer in the body. Hence accelerated diffusion testing is 
essential. For electronics, such tests are typically done using 
elevated temperatures. Diffusion and corresponding Mean 
Time To Failure (MTTF) are related to time and temperature, 
as expressed in the well known Arrhenius equation [6]: 
   MTTF = A exp (-Ea / kT) 
 
    With: A:  pre-exponential constant    Ea: activation energy 
             T : temperature in Kelvin         k : Boltzmann’s constant 
Performing cell cultures at elevated temperatures is out of 
question: above 45-50°C proteins of the cells and in the 
medium start to denaturize, resulting in cell death.   
Elution tests at elevated temperatures can be used to 
evaluate Cu diffusion. We test typically at 70°C (high 
temperature elution conditions according to USP standard). 
After the elution period, the biofluid will be analyzed, to 
detect very small traces of Cu. We developed a sensitive Cu 
detection technique in house, based on TXRF analysis [5].  
Also for long term bio-stability tests, these accelerated test 
procedures are an interesting alternative. Obviously, certain 
material/biofluid reactions might occur only at temperatures 
> 37°C, hence when an interaction is observed at 70°C, a real 
time test at 37°C has to be performed too, to check the 
validity of the 70°C test result. 
Accelerated biostability tests on the insulating and conductive 
materials revealed surprising results. We found that the 
nitride layer slowly dissolves in water based solutions, the 
dissolution rate is low and dependent on the nitride 
deposition process. For long term implants, even a low 
dissolution rate is unacceptable, hence an extra capping layer 
is essential to prevent direct contact between nitride and the 
biofluids. Silicon-carbide (SiC) proved to have a much higher 
biostability and will be used as an extra capping layer.    
Also for the conductive materials, long term biostability 
problems were observed in some biofluids such as DMEM. 
Also here an extra capping layer is applied to protect the 
conductive materials from direct contact with biofluids. 
Platinum will be used; since this material is not compatible 
with CMOS processing, it will be applied after all clean room 
processing. More info can be found in [7].  
Corrosion tests 
We fabricated a corrosion test device to investigate the 
encapsulation of phase 1. The device is carrying long copper 
interconnects on chip, using the encapsulation processes as 
mentioned before and illustrated in Fig.6. Extra electrodes, 
the weakest point regarding corrosion, are added to the Cu 
interconnects to create a worst case scenario for corrosion. 
The Cu interconnects have varying line widths (500nm to 
50µm). For electrode fabrication, the contact pads are 
covered with 15nm Ta, 40nm TaN and 50nm Pt.  
Passive accelerated tests proved no corrosion occurs (no 










Fig 6. Corrosion test device (schematic) 
 
incubation at 70°C, which corresponds to ~ 8 months stability 
against corrosion at 37°C. In active tests, the device is 
immersed in a biofluid (PBS) except for the main contact pads 
at which 1 mA AC or DC current is applied. Meanwhile the 
voltage across the device is monitored. So far the devices 
have proven to be corrosion-free for 2 weeks. Longer term 
and accelerated active tests are ongoing.  
Interconnects 
For the interconnects between various components in phase 
2 and 3 of the packaging, various requirements should be 
combined such as excellent biocompatibility and bio-stability, 
low impedance, good mechanical properties and cost. Very 
interesting materials for these interconnects are Pt and Au. 
Since these packaging phases will take place outside the clean 
room, Pt and Au can be used. These noble metals are 
expensive, hence a cost effective deposition technique should 
be applied. We are currently developing a selective Pt plating 
technique, which will be compared with the more 
conventional lift-off technique for Pt patterning. 
Encapsulation in polymers. 
In phase 2 of the packaging procedure, all chips are 
encapsulated in a polymer. For many years, imec developed a 
Ultra-Thin-Chip-Package (UTCP) process. The metallization 
used for standard UTCP is still copper; as described above a 
new Pt metallization technique is under development, this 
will enable the fabrication of a Pt-based thin chip package.  
In phase 3 of the packaging sequence, all components are 
assembled, interconnected and embedded in a flexible 
biocompatible elastomer. At the sensor location, this 
elastomer embedding should be adjusted in order to enable 
high sensitivity of the sensor. For electrodes for example, the 
elastomer should have a window to allow direct contact 







Fig 7. Imec’s ultra thin chip package (UTCP) technology.  
Left, a cross section showing the thinned die packaged in 










Fig 8. Silicone molding technology using biomedical grade 
silicone to make an implantable bladder sensor.  
Left: details of the silicone embedding at the sensor location  
 
the elastomer should be locally very thin, in order to realize 
hermeticity without losing sensor functionality, as shown in 
Fig. 7. This medical device –an implant measuring the bladder 
pressure- is encapsulated using Silastic MDX4-4210, a 
biomedical grade silicone from Dow Corning [8]. This device is 
still fabricated using conventional Copper metallization.  In 
vitro cytotoxicity tests are performed in accordance with the 
ISO 10993-1 guidelines, showing that the applied silicone 
encapsulation functions as a good seal for at least 8 days [9]. 
As explained before, a superior Pt-based metallization 
scheme for implants is under development, which will make 
the packaging approach suitable for long term implants.  
CONCLUSIONS  
A miniaturized, biocompatible packaging method is proposed, 
resulting in a small, soft and comfortable implantable 
package. For phase 1 of this packaging concept various 
common insulating and conductive clean room materials are 
tested with respect to their suitability as biocompatible and 
biostable barrier layers. To realize a biocompatible 
metallization in phase 2 and 3, a Pt deposition technique is 
under development. Die embedding in polyimide and global 
system embedding in elastomers is explored, although the Cu 
metallization currently applied has still to be replaced by Pt 
metallization for biocompatibility.  
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